A Phase 2 interventional study of Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet) and Part A: zibotentan (dose B) + dapagliflozin in Liver Cirrhosis, sponsored by AstraZeneca. Terminated at 50 sites in 15 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by AstraZeneca · Phase 2, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Liver Cirrhosis by AstraZeneca — 1 open to participants now, 1 under way, none of them phase 3. Liver Cirrhosis · AstraZeneca.
Among the 11 studies in Liver Cirrhosis by AstraZeneca, this one is the 2nd largest by enrollment, is one of 2 that started in 2022, is one of 6 in phase 2, and was the 2nd registered.
1,301 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.
Browse Liver Cirrhosis studies →1 of the 11 studies in Liver Cirrhosis by AstraZeneca is open now, in 2 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Puerto Rico
Ages 18+
By country, each count listing its studies:
Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2022; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 205 is above the median of 78 across 742 interventional studies indexed under Liver Cirrhosis.
Median enrollment 40 across the 11 interventional studies. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
1 of the studies in Liver Cirrhosis by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07610837AstraZenecaStudy of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis | 2027-07-07 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Liver Cirrhosis by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a two part Phase IIa/b multicentre, randomised, double-blind, placebo-controlled, parallel group dose-ranging study to assess the efficacy, safety, and tolerability of the combination of zibotentan and dapagliflozin, and dapagliflozin monotherapy versus placebo in participants with cirrhosis with features of portal hypertension.
Part A will assess the efficacy, safety, and tolerability of the combination of B mg zibotentan and 10 mg dapagliflozin versus placebo in participants with Child-Pugh A cirrhosis with features of portal hypertension and with no history of decompensation events.
If the safety profile is determined to be acceptable at the conclusion of Part A, Part B will investigate efficacy, safety, and tolerability of A mg, B mg, or C mg zibotentan combined with 10 mg dapagliflozin and of 10 mg dapagliflozin monotherapy versus placebo in participants with cirrhosis with features of portal hypertension. Part B will include a broader range of Child- Pugh A and Child-Pugh B cirrhosis participants, including those with more severe disease, a history of decompensation events, or current ascites.
The study will be conducted in approximately 30 to 45 study centres in North America, Asia, and Europe.
Study principal inclusion criteria For both Part A and Part B
Female participants of non- confirmed at screening by fulfilling one of the following criteria:
Part A participants who have the following:
Part B participants who have the following:
Study principal exclusion criteria:
Medical Conditions (Part A only)
Medical Conditions (Part B only)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive once daily dose of placebo matching zibotentan capsule + placebo matching dapagliflozin tablet for 6 weeks.
Drug: Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)
Participants will receive once daily dose of zibotentan capsule + dapagliflozin tablet for 6 weeks.
Drug: Part A: zibotentan (dose B) + dapagliflozin
Participants will receive once daily dose of placebo matching zibotentan capsule + placebo matching dapagliflozin tablet for 16 weeks.
Drug: Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)
Participants will receive once daily dose of placebo matching zibotentan capsule + dapagliflozin tablet for 16 weeks.
Drug: Part B: placebo (matching zibotentan capsule) + dapagliflozin
Participants will receive once daily dose of zibotentan capsule + dapagliflozin tablet for 16 weeks.
Drug: Part B: zibotentan (dose A) + dapagliflozin
Participants will receive once daily dose of zibotentan capsule + dapagliflozin tablet for 16 weeks.
Drug: Part B: zibotentan (dose B) + dapagliflozin
Participants will receive once daily dose of zibotentan capsule + dapagliflozin tablet for 16 weeks.
Drug: Part B: zibotentan (dose C) + dapagliflozin
placebo capsule (matching zibotentan capsule) placebo tablet (matching dapagliflozin tablet)
Drug pages: ZD4054 · Dapagliflozin
zibotentan capsule dapagliflozin tablet
placebo capsule (matching zibotentan capsule) placebo tablet (matching dapagliflozin tablet)
placebo capsule (matching zibotentan capsule) dapagliflozin tablet
Drug pages: ZD4054 · Dapagliflozin
zibotentan capsule dapagliflozin tablet
Drug pages: ZD4054 · Dapagliflozin
zibotentan capsule dapagliflozin tablet
Drug pages: ZD4054 · Dapagliflozin
zibotentan capsule dapagliflozin tablet
Absolute Change in HVPG From Baseline to Week 6, Part A
Absolute change in Hepatic venous pressure gradient from baseline to week 6.
Time frame: From Baseline to Week 6
Absolute Change in HVPG From Baseline to Week 6, Part B
Absolute change in Hepatic venous pressure gradient from baseline to week 6.
Time frame: From Baseline to Week 6
HVPG Percentage Change From Baseline to Week 6, Part A
Hepatic venous pressure gradient percentage change from baseline to week 6, Part A.
Time frame: From Baseline to Week 6
HVPG Percentage Change From Baseline to Week 6, Part B
Hepatic venous pressure gradient percentage change from baseline to week 6, Part B.
Time frame: From baseline to week 6
Number of Participants With HVPG Response at Week 6, Part A
A HVPG responder is defined as a subject having \<10 mmHg at week 6 if baseline HVPG \>=10 or a reduction of \>=1.5 mmHg from baseline to week 6. n: Number of subjects in analysis. N: Number of subjects per treatment group.
Time frame: From baseline to week 6
Number of Participants With HVPG Response at Week 6, Part B
A HVPG responder in Part B is defined as a subject having at least 20% decrease or a reduction to or below 12 mmHg if baseline HVPG \> 12 mmHG from baseline to Week 6.
Time frame: From baseline to Week 6
Change in Body Weight (kg) Over Time Course of Study, Part A
The analysis is performed using MMRM. The model includes the continuous covariate of the Baseline measurements as the fixed effect covariate and fixed categorical effects of treatment group, visit, and treatmentby-visit interaction.
Time frame: From baseline to Week 6
Change in Body Weight (kg) Over Time Course of Study, Part B
The analysis is performed using MMRM. The model includes the continuous covariate of the Baseline measurements as the fixed effect covariate and fixed categorical effects of treatment group, visit, and treatmentby-visit interaction.
Time frame: From baseline to Week 6 and Week 16
Change in Total Dosage of Loop-diuretic Equivalents Use From Baseline to Week 6, Part A
Change in total dosage of loop-diuretic equivalents use from baseline to Week 6, Part A. A loop-diuretic equivalent is based on 40 mg furosemide = 1 mg bumetanide = 20 mg torsemide = 50 mg ethacrynic acid.
Time frame: From baseline to Week 6
Change in Total Dosage of Loop-diuretic Equivalents Use From Baseline to Week 6 and Week 16, Part B
Change in total dosage of loop-diuretic equivalents use from baseline to Week 6, Part B. A loop-diuretic equivalent is based on 40 mg furosemide = 1 mg bumetanide = 20 mg torsemide = 50 mg ethacrynic acid.
Time frame: From Baseline to Week 6 and Week 16
Change in Total Body Water From Baseline to Week 6, Part A
Change in total body water from baseline to Week 6, Part A. The analysis is performed using MMRM.
Time frame: From Baseline to Week 6
Change in Total Body Water From Baseline to Week 6 and Week 16, Part B
Change in total body water from baseline to Week 6 and Week 16, Part B. The analysis is performed using MMRM.
Time frame: From Baseline to Week 6 and Week 16
Change in Extracellular Water From Baseline to Week 6, Part A
Change in extracellular water from baseline to Week 6, Part A. The analysis is performed using MMRM. Bioimpedance spectroscopy (BIS) was performed at the study centre to monitor body water volumes and body fat mass.
Time frame: From baseline to Week 6
Change in Extracellular Water From Baseline to Week 6 and Week 16, Part B
Change in extracellular water from baseline to Week 6 and Week 16, Part B. The analysis is performed using MMRM. Bioimpedance spectroscopy (BIS) was performed at the study centre to monitor body water volumes and body fat mass.
Time frame: From Baseline to Week 6 and to Week 16
Change in Intracellular Water From Baseline to Week 6, Part A
Change in intracellular water from Baseline to Week 6, Part A. The analysis is performed using MMRM. Bioimpedance spectroscopy (BIS) was performed at the study centre to monitor body water volumes and body fat mass.
Time frame: From Baseline to Week 6
Change in Intracellular Water From Baseline to Week 6 and Week 16, Part B
Change in intracellular water from Baseline to Week 6 and Week 16, Part B. The analysis is performed using MMRM. Bioimpedance spectroscopy (BIS) was performed at the study centre to monitor body water volumes and body fat mass.
Time frame: From Baseline to Week 6 and Week 16
Change in Total Body Fat Mass From Baseline to Week 6, Part A
Change in total body fat mass from Baseline to Week 6, Part A. The analysis is performed using MMRM. Bioimpedance spectroscopy (BIS) was performed at the study centre to monitor body water volumes and body fat mass.
Time frame: From baseline to Week 6
Change in Total Body Fat Mass From Baseline to Week 6 and Week 16, Part B
Change in total body fat mass from Baseline to Week 6 and Week 16, Part B. The analysis is performed using MMRM. Bioimpedance spectroscopy (BIS) was performed at the study centre to monitor body water volumes and body fat mass.
Time frame: From Baseline to Week 6 and Week 16
Change in Systolic Blood Pressure From Baseline to Week 6, Part A
Change in systolic blood pressure from baseline to Week 6, Part A. The analysis is performed using MMRM.
Time frame: From Baseline to Week 6
Change in Systolic Blood Pressure From Baseline to Week 6 and Week 16, Part B
Change in systolic blood pressure from baseline to Week 6 and Week 16, Part B. The analysis is performed using MMRM.
Time frame: From baseline to Week 6 and Week 16
Change in Diastolic Blood Pressure From Baseline to Week 6, Part A
Change in diastolic blood pressure from baseline to Week 6, Part A. The analysis is performed using MMRM.
Time frame: From Baseline to Week 6
Change in Diastolic Blood Pressure From Baseline to Week 6 and Week 16, Part B
Change in diastolic blood pressure from baseline to Week 6 and Week 16, Part B. The analysis is performed using MMRM.
Time frame: From baseline to Week 6 and Week 16
This study was conducted at a total of 50 study centers in 15 countries: Australia (1), Austria (1), Belgium (1), China (4), Czech Republic (2), Denmark (4), France (4), Germany (5), Netherlands (1), Romania (1), Spain (7), Switzerland (3), Taiwan (2), United Kingdom (3) and United States (11). First subject enrolled: 31 Oct 2022 and Last subject last visit: 17 Jul 2025.
| Milestone | Part A Zibo/Dapa 2.5 mg/10 mg | Part A Placebo | Part B Dapa 10 mg | Part B Zibo/Dapa 1 mg/10 mg | Part B Zibo/Dapa 2.5 mg/10 mg | Part B Zibo/Dapa 5 mg/10 mg | Part B Placebo |
|---|---|---|---|---|---|---|---|
| Started | 14 | 14 | 35 | 35 | 36 | 36 | 35 |
| Completed | 13 | 13 | 24 | 25 | 24 | 19 | 25 |
| Not completed | 1 | 1 | 11 | 10 | 12 | 17 | 10 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 8 | 6 | 5 | 8 | 7 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 | 0 | 1 | 1 |
| Withdrew: Withdrawn from study due to subject decision | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 1 | 3 | 5 | 5 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 0 | 0 | 3 | 0 |
| Withdrew: Subjects randomised, not treated | 0 | 0 | 1 | 1 | 2 | 0 | 0 |
Absolute change in Hepatic venous pressure gradient from baseline to week 6.
| mmHg | Part A Zibo/Dapa 2.5 mg/10 mg | Part A Placebo |
|---|---|---|
| Absolute Change in HVPG From Baseline to Week 6, Part A | 0.13 (-0.79 to 1.05) | -0.89 (-1.81 to 0.03) |
Absolute change in Hepatic venous pressure gradient from baseline to week 6.
| mmHg | Part B Dapa 10 mg | Part B Zibo/Dapa 1 mg/10 mg | Part B Zibo/Dapa 2.5 mg/10 mg | Part B Zibo/Dapa 5 mg/10 mg | Part B Placebo |
|---|---|---|---|---|---|
| Absolute Change in HVPG From Baseline to Week 6, Part B | -0.56 (-1.34 to 0.22) | -1.48 (-2.31 to -0.64) | 0.02 (-0.79 to 0.83) | -1.02 (-1.93 to -0.11) | -1.37 (-2.16 to -0.59) |
Hepatic venous pressure gradient percentage change from baseline to week 6, Part A.
| percentage change | Part A Zibo/Dapa 2.5 mg/10 mg | Part A Placebo |
|---|---|---|
| HVPG Percentage Change From Baseline to Week 6, Part A | 3.20 (-4.41 to 10.82) | -6.21 (-13.75 to 1.33) |
Hepatic venous pressure gradient percentage change from baseline to week 6, Part B.
| percentage change | Part B Dapa 10 mg | Part B Zibo/Dapa 1 mg/10 mg | Part B Zibo/Dapa 2.5 mg/10 mg | Part B Zibo/Dapa 5mg/10 mg | Part B Placebo |
|---|---|---|---|---|---|
| HVPG Percentage Change From Baseline to Week 6, Part B | -3.62 (-8.54 to 1.31) | -8.93 (-14.33 to -3.52) | 0.29 (-4.81 to 5.39) | -5.66 (-11.26 to -0.06) | -7.64 (-12.56 to -2.71) |
A HVPG responder is defined as a subject having \<10 mmHg at week 6 if baseline HVPG \>=10 or a reduction of \>=1.5 mmHg from baseline to week 6. n: Number of subjects in analysis. N: Number of subjects per treatment group.
| Participants | Part A Zibo/Dapa 2.5 mg/10 mg | Part A Placebo |
|---|---|---|
| Number of Participants With HVPG Response at Week 6, Part A | 5 | 4 |
A HVPG responder in Part B is defined as a subject having at least 20% decrease or a reduction to or below 12 mmHg if baseline HVPG \> 12 mmHG from baseline to Week 6.
| Participants | Part B Dapa 10 mg | Part B Zibo/Dapa 1 mg/10 mg | Part B Zibo/Dapa 2.5 mg/10 mg | Part B Zibo/Dapa 5 mg/10 mg | Part B Placebo |
|---|---|---|---|---|---|
| Number of Participants With HVPG Response at Week 6, Part B | 8 | 10 | 4 | 7 | 9 |
The analysis is performed using MMRM. The model includes the continuous covariate of the Baseline measurements as the fixed effect covariate and fixed categorical effects of treatment group, visit, and treatmentby-visit interaction.
| kg | Part A Zibo/Dapa 2.5 mg/10 mg | Part A Placebo |
|---|---|---|
| Change in Body Weight (kg) Over Time Course of Study, Part A | -1.01 (-1.75 to -0.27) | -0.25 (-1.06 to 0.56) |
The analysis is performed using MMRM. The model includes the continuous covariate of the Baseline measurements as the fixed effect covariate and fixed categorical effects of treatment group, visit, and treatmentby-visit interaction.
| kg | Part B Dapa 10 mg | Part B Zibo/Dapa 1 mg/10 mg | Part B Zibo/Dapa 2.5 mg/10 mg | Part B Zibo/Dapa 5 mg/10 mg | Part B Placebo |
|---|---|---|---|---|---|
| Week 6 | -0.74 (-1.41 to -0.08) | -0.21 (-0.89 to 0.46) | -0.73 (-1.41 to -0.05) | -0.87 (-1.55 to -0.18) | 0.15 (-0.51 to 0.80) |
| Week 16 | -1.13 (-2.07 to -0.18) | -1.31 (-2.24 to -0.38) | -0.63 (-1.58 to 0.31) | -1.27 (-2.27 to -0.27) | 1.02 (0.11 to 1.93) |
Change in total dosage of loop-diuretic equivalents use from baseline to Week 6, Part A. A loop-diuretic equivalent is based on 40 mg furosemide = 1 mg bumetanide = 20 mg torsemide = 50 mg ethacrynic acid.
| 40 mg furosemide equivalents | Part A Zibo/Dapa 2.5 mg/10 mg | Part A Placebo |
|---|---|---|
| Change in Total Dosage of Loop-diuretic Equivalents Use From Baseline to Week 6, Part A | 0.8 (0.0 to 1.6) | 0.0 (-0.8 to 0.8) |
Change in total dosage of loop-diuretic equivalents use from baseline to Week 6, Part B. A loop-diuretic equivalent is based on 40 mg furosemide = 1 mg bumetanide = 20 mg torsemide = 50 mg ethacrynic acid.
| 40 mg furosemide equivalents | Part B Dapa 10 mg | Part B Zibo/Dapa 1 mg/10 mg | Part B Zibo/Dapa 2.5 mg/10 mg | Part B Zibo/Dapa 5 mg/10 mg | Part B Placebo |
|---|---|---|---|---|---|
| Week 6 | -0.018 (-2.804 to 2.769) | 2.931 (-1.226 to 7.087) | 2.894 (0.072 to 5.717) | 7.084 (3.390 to 10.777) | -0.044 (NA to NA) |
| Week 16 | 2.838 (-3.898 to 9.573) | 9.462 (-2.177 to 21.101) | 11.154 (4.274 to 18.033) | 23.629 (13.404 to 33.855) | 4.344 (NA to NA) |
Change in total body water from baseline to Week 6, Part A. The analysis is performed using MMRM.
| L | Part A Zibo/Dapa 2.5 mg/10 mg | Part A Placebo |
|---|---|---|
| Change in Total Body Water From Baseline to Week 6, Part A | 0.7 (0 to 1.5) | 0.5 (-0.3 to 1.3) |
Change in total body water from baseline to Week 6 and Week 16, Part B. The analysis is performed using MMRM.
| L | Part B Dapa 10 mg | Part B Zibo/Dapa 1 mg/10 mg | Part B Zibo/Dapa 2.5 mg/10 mg | Part B Zibo/Dapa 5 mg/10 mg | Part B Placebo |
|---|---|---|---|---|---|
| Week 6 | -0.18 (-0.67 to 0.31) | 0.07 (-0.43 to 0.58) | 0.48 (-0.02 to 0.98) | 0.39 (-0.12 to 0.90) | -0.12 (-0.61 to 0.36) |
| Week 16 | -0.46 (-1.02 to 0.10) | 0.05 (-0.49 to 0.60) | 0.80 (0.25 to 1.36) | 0.48 (-0.13 to 1.08) | 0.31 (-0.23 to 0.84) |
Change in extracellular water from baseline to Week 6, Part A. The analysis is performed using MMRM. Bioimpedance spectroscopy (BIS) was performed at the study centre to monitor body water volumes and body fat mass.
| L | Part A Zibo/Dapa 2.5 mg/10 mg | Part A Placebo |
|---|---|---|
| Change in Extracellular Water From Baseline to Week 6, Part A | 0.2 (-0.6 to 1.1) | 1.1 (0.2 to 2.0) |
Change in extracellular water from baseline to Week 6 and Week 16, Part B. The analysis is performed using MMRM. Bioimpedance spectroscopy (BIS) was performed at the study centre to monitor body water volumes and body fat mass.
| L | Part B Dapa 10 mg | Part B Zibo/Dapa 1 mg/10 mg | Part B Zibo/Dapa 2.5 mg/10 mg | Part B Zibo/Dapa 5 mg/10 mg | Part B Placebo |
|---|---|---|---|---|---|
| Week 6 | -0.14 (-0.39 to 0.10) | 0.12 (-0.13 to 0.37) | 0.37 (0.12 to 0.62) | 0.25 (0.00 to 0.51) | -0.09 (-0.33 to 0.15) |
| Week 16 | -0.26 (-0.54 to 0.02) | 0.08 (-0.19 to 0.35) | 0.36 (0.08 to 0.63) | 0.50 (0.20 to 0.80) | 0.11 (-0.15 to 0.38) |
Change in intracellular water from Baseline to Week 6, Part A. The analysis is performed using MMRM. Bioimpedance spectroscopy (BIS) was performed at the study centre to monitor body water volumes and body fat mass.
| L | Part A Zibo/Dapa 2.5 mg/10 mg | Part A Placebo |
|---|---|---|
| Change in Intracellular Water From Baseline to Week 6, Part A | 0.1 (-0.1 to 1.3) | -0.7 (-1.9 to 0.4) |
Change in intracellular water from Baseline to Week 6 and Week 16, Part B. The analysis is performed using MMRM. Bioimpedance spectroscopy (BIS) was performed at the study centre to monitor body water volumes and body fat mass.
| L | Part B Dapa 10 mg | Part B Zibo/Dapa 1 mg/10 mg | Part B Zibo/Dapa 2.5 mg/10 mg | Part B Zibo/Dapa 5 mg/10 mg | Part B Placebo |
|---|---|---|---|---|---|
| Week 6 | -0.02 (-0.30 to 0.26) | -0.10 (-0.39 to 0.18) | 0.16 (-0.12 to 0.45) | 0.10 (-0.19 to 0.39) | -0.06 (-0.34 to 0.21) |
| Week 16 | -0.21 (-0.50 to 0.08) | -0.02 (-0.30 to 0.26) | 0.15 (-0.14 to 0.44) | 0.03 (-0.28 to 0.34) | 0.16 (-0.12 to 0.43) |
Change in total body fat mass from Baseline to Week 6, Part A. The analysis is performed using MMRM. Bioimpedance spectroscopy (BIS) was performed at the study centre to monitor body water volumes and body fat mass.
| kg | Part A Zibo/Dapa 2.5 mg/10 mg | Part A Placebo |
|---|---|---|
| Change in Total Body Fat Mass From Baseline to Week 6, Part A | 1.9 (-2.5 to 6.2) | 0.1 (-4.7 to 5.0) |
Change in total body fat mass from Baseline to Week 6 and Week 16, Part B. The analysis is performed using MMRM. Bioimpedance spectroscopy (BIS) was performed at the study centre to monitor body water volumes and body fat mass.
| kg | Part B Dapa 10 mg | Part B Zibo/Dapa 1 mg/10 mg | Part B Zibo/Dapa 2.5 mg/10 mg | Part B Zibo/Dapa 5 mg/10 mg | Part B Placebo |
|---|---|---|---|---|---|
| Week 6 | -0.91 (-3.64 to 1.82) | 0.58 (-2.21 to 3.37) | -5.86 (-8.63 to -3.10) | -4.78 (-7.55 to -2.00) | 0.72 (-1.97 to 3.41) |
| Week 16 | -1.69 (-4.69 to 1.32) | -4.54 (-7.52 to -1.56) | -5.58 (-8.59 to -2.57) | -6.42 (-9.66 to -3.18) | 2.35 (-0.56 to 5.26) |
Change in systolic blood pressure from baseline to Week 6, Part A. The analysis is performed using MMRM.
| mmHg | Part A Zibo/Dapa 2.5 mg/10 mg | Part A Placebo |
|---|---|---|
| Change in Systolic Blood Pressure From Baseline to Week 6, Part A | -12.4 (-20.4 to -4.4) | 7.9 (-0.4 to 16.1) |
Change in systolic blood pressure from baseline to Week 6 and Week 16, Part B. The analysis is performed using MMRM.
| mmHg | Part B Dapa 10 mg | Part B Zibo/Dapa 1 mg/10 mg | Part B Zibo/Dapa 2.5 mg/10 mg | Part B Zibo/Dapa 5 mg/10 mg | Part B Placebo |
|---|---|---|---|---|---|
| Week 6 | -3.1 (-6.3 to 0.2) | -6.0 (-9.3 to -2.7) | -8.9 (-12.2 to -5.6) | -7.9 (-11.3 to -4.5) | -3.3 (-6.5 to -0.1) |
| Week 16 | -2.2 (-5.9 to 1.6) | -9.1 (-12.7 to -5.5) | -6.3 (-10.1 to -2.6) | -4.5 (-8.5 to -0.4) | -4.6 (-8.2 to -1.1) |
Change in diastolic blood pressure from baseline to Week 6, Part A. The analysis is performed using MMRM.
| mmHg | Part A Zibo/Dapa 2.5 mg/10 mg | Part A Placebo |
|---|---|---|
| Change in Diastolic Blood Pressure From Baseline to Week 6, Part A | -9.0 (-11.7 to -6.4) | 0.5 (-2.3 to 3.3) |
Change in diastolic blood pressure from baseline to Week 6 and Week 16, Part B. The analysis is performed using MMRM.
| mmHg | Part B Dapa 10 mg | Part B Zibo/Dapa 1 mg/10 mg | Part B Zibo/Dapa 2.5 mg/10 mg | Part B Zibo/Dapa 5 mg/10 mg | Part B Placebo |
|---|---|---|---|---|---|
| Week 6 | 0.0 (-2.0 to 2.1) | -5.5 (-7.6 to -3.5) | -6.7 (-8.8 to -4.6) | -7.3 (-9.4 to -5.2) | -1.6 (-3.6 to 0.4) |
| Week 16 | -0.8 (-3.2 to 1.6) | -4.5 (-6.8 to -2.2) | -4.4 (-6.8 to -2.1) | -2.6 (-5.1 to -0.1) | -2.1 (-4.4 to 0.1) |
Collected over Time frame for AE: Adverse events are included from the On + off treatment periods, ie, AEs with an onset date on or after the date of first IP through study competition, planned visit date (Day 127).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A Zibo/Dapa 2.5 mg/10 mg | 0/14 (0%) | 0/14 (0%) | 10/14 (71.4%) |
| Part A Placebo | 0/14 (0%) | 0/14 (0%) | 9/14 (64.3%) |
| Part B Dapa 10 mg | 0/34 (0%) | 5/34 (14.7%) | 20/34 (58.8%) |
| Part B Zibo/Dapa 1 mg/10 mg | 0/34 (0%) | 6/34 (17.6%) | 17/34 (50%) |
| Part B Zibo/Dapa 2.5 mg/10 mg | 0/34 (0%) | 3/34 (8.8%) | 21/34 (61.8%) |
| Part B Zibo/Dapa 5 mg/10 mg | 0/36 (0%) | 5/36 (13.9%) | 26/36 (72.2%) |
| Part B Placebo | 0/35 (0%) | 4/35 (11.4%) | 16/35 (45.7%) |
| Event | Part A Zibo/Dapa 2.5 mg/10 mg | Part A Placebo | Part B Dapa 10 mg | Part B Zibo/Dapa 1 mg/10 mg | Part B Zibo/Dapa 2.5 mg/10 mg | Part B Zibo/Dapa 5 mg/10 mg | Part B Placebo |
|---|---|---|---|---|---|---|---|
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/14 | 0/14 | 2/34 | 0/34 | 0/34 | 1/36 | 0/35 |
| AscitesGastrointestinal disorders | 0/14 | 0/14 | 0/34 | 2/34 | 0/34 | 2/36 | 0/35 |
| Precancerous lesion of digestive tractGastrointestinal disorders | 0/14 | 0/14 | 1/34 | 0/34 | 0/34 | 0/36 | 0/35 |
| Cardiac failureCardiac disorders | 0/14 | 0/14 | 0/34 | 1/34 | 0/34 | 0/36 | 0/35 |
| Escherichia bacteraemiaInfections and infestations | 0/14 | 0/14 | 1/34 | 0/34 | 0/34 | 0/36 | 0/35 |
| Coronary artery diseaseCardiac disorders | 0/14 | 0/14 | 0/34 | 1/34 | 0/34 | 0/36 | 0/35 |
| Pneumonia escherichiaInfections and infestations | 0/14 | 0/14 | 1/34 | 0/34 | 0/34 | 0/36 | 0/35 |
| Radius fractureInjury, poisoning and procedural complications | 0/14 | 0/14 | 0/34 | 0/34 | 1/34 | 0/36 | 0/35 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/14 | 0/14 | 0/34 | 1/34 | 0/34 | 0/36 | 0/35 |
| Hepatic encephalopathyNervous system disorders | 0/14 | 0/14 | 0/34 | 1/34 | 1/34 | 0/36 | 0/35 |
| Event | Part A Zibo/Dapa 2.5 mg/10 mg | Part A Placebo | Part B Dapa 10 mg | Part B Zibo/Dapa 1 mg/10 mg | Part B Zibo/Dapa 2.5 mg/10 mg | Part B Zibo/Dapa 5 mg/10 mg | Part B Placebo |
|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 4/14 | 3/14 | 3/34 | 3/34 | 7/34 | 15/36 | 1/35 |
| Oedema peripheralGeneral disorders | 2/14 | 1/14 | 4/34 | 5/34 | 9/34 | 11/36 | 3/35 |
| HypotensionVascular disorders | 2/14 | 1/14 | 2/34 | 3/34 | 5/34 | 3/36 | 0/35 |
| DiarrhoeaGastrointestinal disorders | 0/14 | 2/14 | 0/34 | 2/34 | 0/34 | 2/36 | 2/35 |
| FatigueGeneral disorders | 0/14 | 0/14 | 3/34 | 1/34 | 2/34 | 5/36 | 1/35 |
| ConstipationGastrointestinal disorders | 0/14 | 0/14 | 2/34 | 2/34 | 1/34 | 5/36 | 1/35 |
| DizzinessNervous system disorders | 1/14 | 1/14 | 4/34 | 1/34 | 0/34 | 2/36 | 3/35 |
| Orthostatic hypotensionVascular disorders | 0/14 | 1/14 | 2/34 | 1/34 | 4/34 | 1/36 | 4/35 |
| AscitesGastrointestinal disorders | 0/14 | 0/14 | 4/34 | 1/34 | 0/34 | 2/36 | 2/35 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/14 | 0/14 | 0/34 | 0/34 | 0/34 | 4/36 | 1/35 |
Baseline Analysis Population is based on Full Analysis Set, defined as all participants who were randomised and received any IP.
| Age, Continuous(Years) | Part A Zibo/Dapa 2.5 mg/10 mg | Part A Placebo | Part B Dapa 10 mg | Part B Zibo/Dapa 1 mg/10 mg | Part B Zibo/Dapa 2.5 mg/10 mg | Part B Zibo/Dapa 5 mg/10 mg | Part B Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 62.2 ± 7.6 | 66.7 ± 11.7 | 60.6 ± 8.4 | 62.3 ± 10.7 | 61.7 ± 8.7 | 60.9 ± 8.4 | 59.7 ± 9.4 | 61.5 ± 9.3 |
| Age, Customized(Participants) | Part A Zibo/Dapa 2.5 mg/10 mg | Part A Placebo | Part B Dapa 10 mg | Part B Zibo/Dapa 1 mg/10 mg | Part B Zibo/Dapa 2.5 mg/10 mg | Part B Zibo/Dapa 5 mg/10 mg | Part B Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| >=18 - <30 years | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| >=30 - <50 years | 1 | 1 | 3 | 2 | 3 | 2 | 4 | 16 |
| >=50 - <65 years | 7 | 5 | 22 | 16 | 16 | 18 | 18 | 102 |
| >=65 - <=80 years | 6 | 8 | 9 | 15 | 15 | 16 | 13 | 82 |
| Missing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Part A Zibo/Dapa 2.5 mg/10 mg | Part A Placebo | Part B Dapa 10 mg | Part B Zibo/Dapa 1 mg/10 mg | Part B Zibo/Dapa 2.5 mg/10 mg | Part B Zibo/Dapa 5 mg/10 mg | Part B Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 5 | 3 | 12 | 8 | 9 | 8 | 11 | 56 |
| Male | 9 | 11 | 22 | 26 | 25 | 28 | 24 | 145 |
| Race/Ethnicity, Customized(Participants) | Part A Zibo/Dapa 2.5 mg/10 mg | Part A Placebo | Part B Dapa 10 mg | Part B Zibo/Dapa 1 mg/10 mg | Part B Zibo/Dapa 2.5 mg/10 mg | Part B Zibo/Dapa 5 mg/10 mg | Part B Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 1 | 4 | 3 | 4 | 3 | 1 | 20 |
| Missing | 0 | 0 | 0 | 0 | 2 | 3 | 3 | 8 |
| Not Hispanic or Latino | 10 | 13 | 30 | 31 | 28 | 30 | 31 | 173 |
| Race/Ethnicity, Customized(Participants) | Part A Zibo/Dapa 2.5 mg/10 mg | Part A Placebo | Part B Dapa 10 mg | Part B Zibo/Dapa 1 mg/10 mg | Part B Zibo/Dapa 2.5 mg/10 mg | Part B Zibo/Dapa 5 mg/10 mg | Part B Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 4 | 3 | 3 | 4 | 15 |
| Black or African American | 0 | 0 | 1 | 1 | 2 | 2 | 0 | 6 |
| Missing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not reported | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 2 |
| Other | 0 | 0 | 1 | 0 | 5 | 5 | 4 | 15 |
| White | 14 | 14 | 31 | 28 | 24 | 25 | 27 | 163 |
| Region of Enrollment(Participants) | Part A Zibo/Dapa 2.5 mg/10 mg | Part A Placebo | Part B Dapa 10 mg | Part B Zibo/Dapa 1 mg/10 mg | Part B Zibo/Dapa 2.5 mg/10 mg | Part B Zibo/Dapa 5 mg/10 mg | Part B Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Australia | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 3 |
| Austria | 2 | 2 | 3 | 6 | 3 | 3 | 6 | 25 |
| Belgium | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 2 |
| China | 0 | 0 | 1 | 2 | 1 | 2 | 1 | 7 |
| Czech Republic | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 3 |
| Denmark | 0 | 5 | 4 | 2 | 0 | 5 | 1 | 17 |
| France | 0 | 0 | 0 | 0 | 2 | 3 | 4 | 9 |
| Germany | 3 | 1 | 3 | 5 | 3 | 3 | 4 | 22 |
| Netherlands | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 4 |
| Romania | 0 | 0 | 5 | 4 | 3 | 2 | 5 | 19 |
| Spain | 5 | 4 | 7 | 7 | 12 | 9 | 6 | 50 |
| Switzerland | 1 | 2 | 1 | 0 | 0 | 1 | 3 | 8 |
| Taiwan | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 5 |
| United Kingdom | 0 | 0 | 0 | 1 | 3 | 2 | 0 | 6 |
| United States of America | 3 | 0 | 6 | 5 | 3 | 3 | 1 | 21 |
| HVPG(mmHg) | Part A Zibo/Dapa 2.5 mg/10 mg | Part A Placebo | Part B Dapa 10 mg | Part B Zibo/Dapa 1 mg/10 mg | Part B Zibo/Dapa 2.5 mg/10 mg | Part B Zibo/Dapa 5 mg/10 mg | Part B Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 12.68 ± 3.73 | 10.54 ± 3.51 | 16.00 ± 4.24 | 15.24 ± 3.34 | 16.41 ± 3.73 | 15.85 ± 3.75 | 17.23 ± 3.60 | 15.54 ± 4.05 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Oct 2022 to primary completion in May 2025, 30 months.
Results were first posted in Sep 2026, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: ZD4054 · Dapagliflozin